铝佐剂灭活脊髓灰质炎疫苗IPV-Al与标准IPV的免疫原性和安全性比较:一项在6、10、14周龄及9月龄婴儿中接种的3期观察者盲法随机对照试验
在菲律宾5个研究中心开展的3期观察者盲法随机对照试验中,未接种过脊髓灰质炎疫苗的婴儿随机接受3剂IPV-Al(n=502)或标准IPV(n=500),分别在6、10、14周龄接种,并于9月龄加强接种。主要终点为初次系列接种后1个月各型别血清转化率,IPV-Al对3个型别均非劣于标准IPV(95%CI下限均高于预设-10%点),加强免疫应答稳健,两者安全性相似。
要点
- IPV-Al对3个型别血清转化率非劣于标准IPV,95%CI下限均高于-10%点。
- 加强免疫后GMT比值:1型63 vs 43,2型54 vs 47,3型112 vs 80。
- 严重不良事件:IPV-Al组29例(5.8%,37起)vs IPV组28例(5.6%,48起)。
核心结论
- IPV-Al对标准IPV在血清转化方面的非劣效性得到确认,并显示稳健的加强免疫应答,两者安全性特征相似。
研究设计与样本
- 3期观察者盲法随机对照试验,在菲律宾5个研究中心开展。
- 未接种过脊髓灰质炎疫苗的婴儿随机接受IPV-Al(n=502)或IPV(n=500),于6、10、14周龄接种3剂,9月龄加强接种1剂。
- 符合方案集:IPV-Al组483名婴儿,IPV组478名婴儿。
主要发现
- 初次系列接种后1个月血清转化率:1型IPV-Al组97.1% vs IPV组99.0%;2型94.2% vs 99.0%;3型98.3% vs 99.6%。
- 治疗差异(IPV-Al减IPV)95%CI下限均高于预设-10%点:1型-1.85%(-3.85; -0.05);2型-4.75%(-7.28; -2.52);3型-1.24(-2.84; 0.13)。
- 加强免疫效果(加强后GMT/加强前GMT):1型63 vs 43;2型54 vs 47;3型112 vs 80。
- 严重不良事件:IPV-Al组29名婴儿(5.8%,37起事件)vs IPV组28名(5.6%,48起事件)。
关键数值与推荐
- 主要终点为型别特异性血清转化,定义为初次系列接种后1个月抗体滴度较估计母体抗体滴度≥4倍升高且滴度≥8。
- 非劣效界值为治疗差异95%CI下限高于-10%点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A dose-sparing inactivated polio vaccine (IPV-Al), obtained by adsorption of inactivated virus to an aluminium hydroxide adjuvant, can help mitigate global supply and the cost constraints of IPV. The objective of this trial was to demonstrate the non-inferiority of IPV-Al to standard IPV. METHODS: This phase 3, observer-blinded, randomised, controlled trial was conducted at 5 investigational sites in the Philippines. Infants not previously vaccinated with any polio vaccines were randomised to receive three IPV-Al (n = 502) or IPV vaccinations (n = 500) at 6, 10 and 14 weeks of age plus a booster vaccination at 9 months. The primary endpoint was type-specific seroconversion, defined as an antibody titre ≥4-fold higher than the estimated maternal antibody titre and a titre ≥8, one month after the primary vaccination series. RESULTS: Seroconversion rates following primary vaccination with IPV-Al (483 infants in the per-protocol analysis set) or IPV (478 infants) were: polio type 1, 97.1% versus 99.0%; type 2, 94.2% versus 99.0%; and type 3, 98.3% versus 99.6%. IPV-Al was non-inferior to IPV, as the lower 95% confidence limits of the treatment differences were above the predefined -10%-point limit: type 1, -1.85% (-3.85; -0.05); type 2, -4.75% (-7.28; -2.52); type 3, -1.24 (-2.84; 0.13). The booster effect (geometric mean titre (GMT) post-booster / GMT pre-booster) was: type 1, 63 versus 43; type 2, 54 versus 47; type 3, 112 versus 80. IPV-Al was well tolerated with a safety profile comparable to that of IPV. Serious adverse events were recorded for 29 infants (5.8%, 37 events) in the IPV-Al group compared to 28 (5.6%, 48 events) in the IPV group. CONCLUSION: Non-inferiority of IPV-Al to IPV with respect to seroconversion was confirmed and a robust booster response was demonstrated. Both vaccines had a similar safety profile. ClinicalTrials.gov identifier: NCT03032419.
引用
- Bravo LC, Carlos JC, Gatchalian SR, et al. Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age. Vaccine. 2019. PMID: 31703934. doi:10.1016/j.vaccine.2019.10.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。